- Home
- CGBD vs ORIC Comparison
CGBD vs ORIC Comparison
Compare CGBD & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGBD | ORIC |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | 2500 | 104 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.2M | 861.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGBD | ORIC |
|---|---|---|
| Price | $10.69 | $8.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $12.92 | ★ $19.73 |
| AVG Volume (30 Days) | 570.6K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 14.42% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.80 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.64 | $5.51 |
| 52 Week High | $14.32 | $14.93 |
Technical Indicators
Market Signals| Indicator | CGBD | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 37.06 |
| Support Level | $10.68 | $7.90 |
| Resistance Level | $12.17 | $11.22 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 3.80 | 30.75 |
Price Performance
Historical ComparisonAbout CGBD Carlyle Secured Lending Inc.
Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.